FDA Advisors Support BMS/AZ’s Diabetes Drug Forxiga

Drug Industry Daily
A A
After falling behind in the race for new diabetes treatments, partners Bristol-Myers Squibb and AstraZeneca Thursday got a boost in the form of a nearly unanimous recommendation from FDA advisors for their drug Forxiga.

To View This Article:

Login

Subscribe To Drug Industry Daily